Chemotherapy

• 

  Subject Areas on Research

  • Chemotherapy at the End of Life (EOL) for Patients with Lung Cancer within the VA System 
  • INDUCTION CHEMORADIOTHERAPY IS NOT SUPERIOR TO INDUCTION CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE IIIA(N2) NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS 
  • Long-Term Survival after Surgery for Pathologic N1 and N2 Small Cell Lung Cancer: A Comparison with Nonoperative Management 
  • Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, zarnestra) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): North American intergroup study S0432. 
  • Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ) 
  • Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial 
  • Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy 
  • Uterine Neoplasms Clinical Practice Guidelines in Oncology 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Moorman, Patricia Gripka, Professor in Community and Family Medicine, Duke Cancer Institute
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology